This Special Report discusses the management of OIC in patients with advanced illness, including RELISTOR (methylnaltrexone bromide), a second-line therapeutic option that inhibits opioids from binding to target receptors within the GI tract and does not cross the blood-brain barrier.
I am writing this as I return from a UN-based meeting in the USA following up on the meeting at which I was invited to talk about the first Hair for Hospices in 2012. Many remembered my presentation and had participated last year and plan to do so again this year. However, I was very touched by a small number of colleagues who spoke to me privately to tell me of serious and terminal illness that had been diagnosed in their family members since last year.
Conclusion Our study demonstrates widespread use of bevacizumab among patients who had contraindications. Black patients were less likely to receive the drug, but those who did were more likely to have a contraindication. Efforts to understand toxicity and efficacy in populations excluded from clinical trials are needed.
Enalapril and Carvedilol to prevent chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies ONLINE FIRST
via American College of Cardiology Foundation | Journal of the American College of Cardiology | Enalapril and Carvedilol to prevent chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies.
The detrimental effect of chemotherapy on large fibers failed to differentiate painful from painless CIN. Patients stratified for musculoskeletal or neuropathic pain, however, differed in psychological and somatosensory parameters. This stratification might allow for the application of a more specific therapy.
Thus, in dialysis patients, daily enoxaparin for thromboprophylaxis was not associated with increased serious bleeding or less effective compared to subcutaneous heparin.
At the era of IMRT, a high rate of endocrine deficiency was still seen. Hypothalamic–pituitary–thyroid dysfunction is more common in NPC patients. Regular monitoring is needed.
We found that eChIMES was easy to use, understandable, and suitable for monitoring mucositis among children with cancer. Incorporation into clinical trials may improve the ability to compare and evaluate interventions for mucositis.
Rapid advances in drug discovery and the regulatory approval of a number of novel anticancer agents during the past decade pose unique challenges to the oncology community. While the benefits of such therapies receive most attention, adverse events (AEs), especially those pertaining to subspecialties (e.g., dermatology), often are underemphasized. To ensure best clinical outcomes, it would be important to bridge the gap between approval of a new drug and devising effective management strategies for the AEs.